A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Name: A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
License: Public Domain

West China Hospital

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

her2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 230390
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.